Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found a relatively low prevalence of cutaneous reactions in chronic hepatitis C patients treated with peginterferon alfa and ribavirin, with reactions correlated to age and treatment duration.

This study found that dermatological adverse events from interferon-alpha/ribavirin treatment for chronic hepatitis C are associated with factors like older age, pre-existing skin conditions, cirrhosis, and the use of pegylated interferon formulations.

This study found that biliverdin beta and delta, metabolites of heme, play a critical role in Pseudomonas aeruginosa iron acquisition and cooperative behaviors, which are crucial for the bacterium's long-term infection in cystic fibrosis patients, suggesting potential targets for new therapies.

In liver cancer cells, this study found that upregulating hsa_circ_0002980 inhibits cell proliferation, metastasis, and EMT by modulating the miR-1303/CADM2 axis, suggesting it as a potential therapeutic target.

This study reported the development of new pyrazole-based MPC inhibitors that effectively inhibit mitochondrial pyruvate transport, showing potential as therapeutic candidates for conditions like metabolic dysfunction-associated steatohepatitis without activating PPARγ.

In this study, 97% of patients undergoing pegylated interferon alfa2a and ribavirin therapy for chronic hepatitis C experienced one or more skin-related side effects, with hair loss being the most common.

This study found that the compound M50054 inhibits apoptosis by blocking caspase-3 activation and may improve chemotherapy-induced alopecia and hepatitis symptoms.

This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.

This case study highlights the importance of early detection and management of pembrolizumab-induced hepatitis, suggesting that early steroid treatment could potentially prevent severe complications.

This study found that astilbin downregulates effector CD4+ T cell activities through the CYP1B1/ROS/PPARγ pathway, suggesting its potential use in treating inflammation.

This study found that the peptides RMYYY and VMYMI displayed stronger binding energy and more frequent interactions with HPGDS compared to the native inhibitor, suggesting potential as future therapeutic drugs.

In this study, a high daily dose of interferon alfa-2b administered initially six times a week for two weeks followed by thrice weekly for 12 weeks was most effective in sustaining normal ALT values in patients.

In these initial clinical studies, NAP monotherapy showed significant reductions in HBsAg levels among patients with chronic HBV, suggesting potential as part of future combination therapies.

This molecular docking study reported that danoprevir, remdesivir, and saridegib exhibit stronger binding affinities to the main protease of SARS-CoV-2 than the control, suggesting their potential as inhibitors of the virus's replication process.

This review discusses zinc supplementation as a complementary therapy for chronic hepatitis C, noting its potential benefits in improving treatment outcomes and reducing side effects, but reports no new clinical results.

Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.

In this study, baricitinib treatment improved the differentiation of skin-derived precursors into adipocytes for diseases like Hutchinson-Gilford progeria syndrome, suggesting potential benefits when combined with lonafarnib.

This study found that mice genetically modified to overexpress the serine protease inhibitor hurpin showed reduced UV-induced apoptosis but increased susceptibility to skin cancer after chemical carcinogenesis.

This case report details the first known instance of interferon-induced lichen planus in a seronegative HCV patient with metastatic renal cell carcinoma.

In this study, molecular docking simulations and cell-based assays suggested that certain analogues of cepharanthine might possess anti-SARS-CoV-2 activity.

This review highlights that while sonidegib and vismodegib offer promising treatment options for advanced basal cell carcinoma, their use is often limited by treatment-emergent adverse events, which can be managed through protocol modifications and supportive interventions.

In this report, a case of a bullous lesion developed at the injection site in a patient treated with PEG-IFN-α-2a for chronic hepatitis C was described.

This review discusses the current medical treatments for hepatocellular carcinoma, noting that while new local therapies show high response rates, their true impact on patient survival is uncertain.

This study found that forming inclusion complexes of DPCP with HPβCD using the 3D ground mixture method enhances its anti-inflammatory activity at lower doses compared to complexes with β-CD.

This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.

This study identified several compounds, including Pictilisib and Nimorazole, that may have higher binding affinity for SARS-CoV-2 main protease than existing inhibitors, potentially offering new treatment alternatives for Covid-19.

This study found that the PPARγ modulator NAC-GED-0507-Levo may protect hair follicles from chemotherapy-induced damage, potentially offering a strategy to address irreversible hair loss in cancer patients.

In this study of Egyptian patients on hepatitis C treatment, 34% experienced skin-related side effects from sofosbuvir and daclatasvir, such as itching and hyperpigmentation, but most reactions were mild and reversible without needing to stop therapy.

In this study, PEVIII, a nanocomposite chitosan-coated vesicle containing both α-hederin and hederacoside C, demonstrated notable antibacterial activity against Pseudomonas aeruginosa in a keratitis model, showing significant lesion reduction, tissue improvement, and decreased bacterial load and inflammatory markers compared to other treatments.

This study found that recombinant IFN α-2b injections in patients with acute post-transfusion hepatitis C can suppress viral RNA and lead to normalization of serum ALT, though long-term prevention of chronicity remains unclear.